2.30Open2.30Pre Close0 Volume1 Open Interest80.00Strike Price0.00Turnover328.25%IV69.29%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0252Delta0.0003Gamma110.00Leverage Ratio-0.2965Theta-0.0038Rho-2.77Eff Leverage0.0328Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet